Cala Health, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cala Health, Inc.
Korea Readying Itself For New Era Of Digital Therapeutics
Scrip takes a look at the current landscape in the South Korean digital therapeutics sector, where some remaining gaps in regulation and reimbursement are seen but multiple products are now progressing through pivotal local clinical trials.
SK Biopharm's CTO On Diversity In Open Innovation
SK Biopharm’s chief technology officer outlines how the company’s open innovation strategy may vary and what he sees as essential in new drug development.
Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy
Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.
Blue Sky Thinking: CEOs, Analysts Offer Some Thoughts On 2022
As Omicron further destabilizes the medtech space, potentially mirroring the spring of 2020, some executives shared with Medtech Insight their views on what will hopefully be a bumper year for the sector.
- Medical Devices
- Other Names / Subsidiaries
- CALA HEALTH®
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.